PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1α axis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
&NA; Type 2 diabetes mellitus (DM2) follows impaired glucose tolerance in obesity and is frequently associated with hypertension, causing adverse myocardial remodelling and leading to heart failure. The DNA bound protein PARP (poly ADP ribose) polymerase catalyses a post translational modification (polymerization of negatively charged ADP‐ribose chains) of nuclear proteins. PARP‐1 activation is NAD+ dependent and takes part in DNA repair and in chromatin remodelling and has a function in transcriptional regulation, intracellular trafficking and energy metabolism. PARP‐1 is activated in diabetic cardiomyopathy. We hypothesized that PARP‐1 inhibition in diabetic mice may protect cardiomyocytes from inflammation and ROS production. Methods: Obese Leptin resistant (db/db) mice suffering from DM2, were treated with angiotensin II (AT) for 4 weeks to enhance the development of cardiomyopathy. Mice were concomitantly treated with the PARP‐1 inhibitor INO1001. Neonatal cardiomyocytes exposed to high levels of glucose (33 mM) with or without AT were treated with INO1001. or with SIRT inhibitor (EX‐527) in the presence of INO1001 were tested in‐vitro. Results: The in‐vivo tests show that hearts from AT treated DM2 mice exhibited cardiac hypertrophy, fibrosis and an increase in the inflammatory marker TNF&agr;. DM2 mice had an increased oxidative stress, concomitant with elevated PARP‐1 activity and reduced Sirtuin‐1 (SIRT1) expression. PARP‐1 inhibition led to increased SIRT1 and Peroxisome proliferator‐activated receptor gamma coactivator 1‐&agr; (PGC‐1&agr;) levels, attenuating oxidative stress, inflammation and fibrosis. In‐vitro experiments demonstrated that inhibition of PARP‐1 in cardiomyocytes exposed to high levels of glucose and AT led to a significant reduction in ROS (P < 0.01), which was abolished in the presence of the SIRT1 inhibitor together with increased protein expression of SIRT1 and PGC‐1&agr;. Conclusion: PARP1 inhibitor INO1001 attenuated cardiomyopathic features in diabetic mice through the activation of SIRT1 and its downstream antioxidant defence mechanisms. The results of this study suggest a pivotal role of PARP‐1 inhibition in treating diabetic and AT‐induced cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130
Sirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868
Diabetic cardiomyopathy: pathophysiology and clinical features
Miki, T., Yuda, S., Kouzu, H., & Miura, T. (2013) · Heart Failure Reviews · doi:10.1007/s10741-012-9313-3 · Cited by 460
A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways
Gomes, A. P., & Blenis, J. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.12.007 · Cited by 112
Ca2+-induced PARP-1 activation and ANF expression are coupled events in cardiomyocytes
Geistrikh, I., Visochek, L., Klein, R., Miller, L., Mittelman, L., Shainberg, A., & Cohen-Armon, M. (2011) · Biochemical Journal · doi:10.1042/bj20101484 · Cited by 23
Self-citation
Cited by
The sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
NAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627
Qian, L., Zhu, Y., Deng, C., Liang, Z., Chen, J., Chen, Y., Wang, X., Liu, Y., Tian, Y., & Yang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01756-w · Cited by 338
NAD + Metabolism in Cardiac Health, Aging, and Disease
Abdellatif, M., Sedej, S., & Kroemer, G. (2021) · Circulation · doi:10.1161/circulationaha.121.056589 · Cited by 255
Lima, J. E. B. F., Moreira, N. C. S., & Sakamoto-Hojo, E. T. (2022) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2021.503437 · Cited by 203
Metadata
- Authors
- Waldman, M., Nudelman, V., Shainberg, A., Abraham, N. G., Kornwoski, R., Aravot, D., Arad, M., & Hochhauser, E.
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 373
- Issue
- 1-2
- Pages
- 112-118
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W2895936675
- Cited by
- 73
- References
- 7
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1α axis. https://app.cochat.ai/papers/10.1016/j.yexcr.2018.10.003
- The paper
- Waldman, M., Nudelman, V., Shainberg, A., Abraham, N. G., Kornwoski, R., Aravot, D., Arad, M., & Hochhauser, E. (2018). PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1α axis. Experimental Cell Research. https://doi.org/10.1016/j.yexcr.2018.10.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.